Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery

scientific article

Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/02652040802305618
P698PubMed publication ID18720197
P5875ResearchGate publication ID23187178

P2093author name stringIbrahim A Alsarra
P2860cites workMaltodextrin-based proniosomesQ28366138
In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery.Q33270298
Novel mechanisms and devices to enable successful transdermal drug deliveryQ34334041
Liposomes and niosomes as topical drug delivery systemsQ36193206
Feasibility of transdermal delivery of fluoxetineQ41833696
The preparation and properties of niosomes--non-ionic surfactant vesiclesQ41984007
In vitro skin permeation of estradiol from various proniosome formulationsQ43543122
Sensitive LC determination of piroxicam after in vitro transdermal permeation studiesQ43715611
Piroxicam delivery into human stratum corneum in vivo: iontophoresis versus passive diffusion.Q43725883
Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranolQ43750669
Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma modelQ44005705
Cyclodextrin enhanced transdermal delivery of piroxicam and carboxyfluorescein by electroporationQ45081027
In vitro and in vivo percutaneous absorption of topical dosage forms: case studiesQ45262471
Nebulization of liposomes. III. The effects of operating conditions and local environmentQ46082245
Proniosomes as a drug carrier for transdermal delivery of ketorolacQ46370501
Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteersQ46527312
Enhanced efficacy by percutaneous absorption of piroxicam from the poloxamer gel in rats.Q52132079
Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in hexadecyltrimethylammonium bromide based microemulsion.Q52210511
Non-ionic surfactant based vesicles (niosomes) in drug deliveryQ57610510
P433issue3
P304page(s)272-278
P577publication date2008-10-20
P1433published inJournal of MicroencapsulationQ15708887
P1476titleEvaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery
P478volume26

Reverse relations

cites work (P2860)
Q53819702Assessment of simvastatin niosomes for pediatric transdermal drug delivery.
Q85246487Entrapment and release difference resulting from hydrogen bonding interactions in niosome
Q38838736Fabrication and evaluation of Eudragit® polymeric films for transdermal delivery of piroxicam.
Q46754307Nano-proniosomes enhancing the transdermal delivery of mefenamic acid
Q93018045Niosomal Nanocarriers for Enhanced Skin Delivery of Quercetin with Functions of Anti-Tyrosinase and Antioxidant
Q53054958Sustained release of piroxicam from solid lipid nanoparticle as an effective anti-inflammatory therapeutics in vivo.
Q38705821Technology overview and drug delivery application of proniosome